Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 17.76 is 244% above its 5-year average of 5.16, near the high end of its 5-year range (0.95–17.76).
As of the fiscal period ended Tuesday, June 30, 2026. 32.60% above its 12-month average of 13.40.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 17.76.
QUICK RATIO (ACID-TEST)
17.76
QUICK RATIO (ACID-TEST) AVG TTM
13.40
QUICK RATIO (ACID-TEST) AVG 3Y
7.54
QUICK RATIO (ACID-TEST) AVG 5Y
5.16
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+32.60%
CURRENT VS 3Y AVG
+135.73%
CURRENT VS 5Y AVG
+243.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 870 covered companies
CURRENT VS SECTOR MEDIAN
+429.49%
vs the sector median at left
Taysha Gene Therapies, Inc.
Market Cap
$1.40B
Quick Ratio (Acid-Test)
17.76
TTM Avg
13.40
3Y Avg
7.54
5Y Avg
5.16
Market Cap
$1.40B
Quick Ratio (Acid-Test)
11.11
TTM Avg
12.01
3Y Avg
12.01
5Y Avg
12.01
Market Cap
$1.40B
Quick Ratio (Acid-Test)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
Quick Ratio (Acid-Test)
5.61
TTM Avg
9.29
3Y Avg
11.65
5Y Avg
16.84
Market Cap
$1.39B
Quick Ratio (Acid-Test)
1.20
TTM Avg
1.17
3Y Avg
1.13
5Y Avg
1.04
Market Cap
$1.42B
Quick Ratio (Acid-Test)
1.56
TTM Avg
2.29
3Y Avg
2.59
5Y Avg
3.62
Market Cap
$1.37B
Quick Ratio (Acid-Test)
5.07
TTM Avg
3.94
3Y Avg
5.82
5Y Avg
6.31
Market Cap
$1.45B
Quick Ratio (Acid-Test)
2.94
TTM Avg
3.04
3Y Avg
2.84
5Y Avg
2.90
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | $1.40B | 17.76 | 13.40 | 7.54 | 5.16 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 11.11 | 12.01 | 12.01 | 12.01 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 5.61 | 9.29 | 11.65 | 16.84 |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 1.20 | 1.17 | 1.13 | 1.04 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | 1.56 | 2.29 | 2.59 | 3.62 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | 5.07 | 3.94 | 5.82 | 6.31 |
| Certara, Inc. (CERT)vs › | $1.44B | 2.55 | 2.09 | 2.53 | 2.95 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 2.94 | 3.04 | 2.84 | 2.90 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 18.31 | 12.63 | 8.12 | 8.12 |
Quick Ratio
17.76
Excludes inventory
Current Ratio
17.76
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 17.76 |
| 2026-03-31 | 14.04 |
| 2025-12-31 | 12.23 |
| 2025-09-30 | 10.48 |
| 2025-06-30 | 12.48 |
| 2025-03-31 | 5.35 |
| 2024-12-31 | 5.42 |
| 2024-09-30 | 5.51 |
| 2024-06-30 | 5.22 |
| 2024-03-31 | 3.38 |
| 2023-12-31 | 4.08 |
| 2023-09-30 | 0.95 |
| 2023-06-30 | 1.07 |
| 2023-03-31 | 1.33 |
| 2022-12-31 | 1.54 |
| 2022-09-30 | 1.30 |
| 2022-06-30 | 1.79 |
| 2022-03-31 | 2.20 |
| 2021-12-31 | 3.08 |
| 2021-09-30 | 4.56 |
| 2021-06-30 | 7.30 |
| 2021-03-31 | 12.64 |
| 2020-12-31 | 36.17 |
| 2020-09-30 | 24.02 |
| 2020-06-30 | 0.56 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.00 |
